



Press Release

BioApex, s.r.o. signs a License Agreement with OlChemIm, Olomouc, Czech Republic

Olomouc, Czech Republic (May 31, 2009) – BioApex, s.r.o., a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat serious cell cycle related disorders including various cancers, today announced that it has signed a license agreement with OlChemIm, Olomouc, Czech Republic. Under the license agreement, OlChemIm will manufacture for BioApex certain purine derivatives of plant hormone origin in bulk quantities. BioApex intends to sell these purine derivatives in certain markets. A list of the purine derivatives presently sold is posted on BioApex's website.

About BioApex, s.r.o.: BioApex owns a proprietary portfolio of small molecule-like compounds derived from plant hormones.

BioApex plans to initially advance a group of promising compounds on which the design, *in vitro* testing and preclinical trials have been completed, to clinical testing. The selected compounds will be taken through pharmacokinetic studies and pre-clinical efficacy trials to determine development priorities. BioApex's business model - a tiered strategy with some compounds in an advanced stage of development and encouraging results to date and some compounds in the pipeline for development – is tailored to attract both, industry "partners" and – in addition to governmental grants and loans - private equity to fund operations. With limited resources focused on research and development, BioApex plans to partner with strong pharmaceutical companies that have established sales and marketing channels in BioApex's target areas.

BioApex has at its disposal Good Manufacturing Practice (GMP) compliant and fully ISO9001 certified manufacturing facilities with reactor capacity of about 0,5 m³. Multipurpose facilities are continually upgraded and they enable flexibility in custom manufacturing kilogram quantities of products. By intent, our production scale is kept limited. BioApex specializes on biochemicals and plant growth regulators of purine origin. BioApex also produces other substituted purines with high purity (> 99%, HPLC) in kg quantities, such as different nucleosides, nucleotides and di- and trisubstituted purines.

For more information, visit the company's website at www.bioapex.cz